Drug Hyperthermia Summary

Malignant Hyperthermia

  • Triggers: Suxamethonium, volatile anesthetics
  • Key signs: Masseter spasm, ↑ETCO₂, tachycardia
  • Treatment: Stop triggers, dantrolene 2.5mg/kg
  • Emergency: Life-threatening, requires ICU

Neuroleptic Malignant Syndrome

  • Causes: Antipsychotics, dopamine withdrawal
  • Onset: Gradual (days)
  • Features: "Lead-pipe" rigidity, bradykinesia
  • Treatment: Stop drug, supportive care, dantrolene

Serotonin Syndrome

  • Causes: Serotonergic drugs
  • Onset: Rapid (hours)
  • Features: Hyperreflexia, clonus, agitation
  • Treatment: Stop drug, benzodiazepines, cyproheptadine

Key Differences

  • NMS: Hyporeflexia, slow onset
  • SS: Hyperreflexia, rapid onset
  • MH: Anesthesia-related, masseter spasm

Critical Medications

  • MH: Dantrolene
  • NMS: Bromocriptine, amantadine
  • SS: Cyproheptadine, benzodiazepines

Emergency Actions

  • Stop causative agents immediately
  • Aggressive cooling
  • IV fluids and supportive care
  • Monitor for complications
  • ICU admission for severe cases

Drug-Related Hyperthermia

Life-threatening hyperthermic syndromes associated with medication use

Overview

Drug-related hyperthermia encompasses several life-threatening conditions characterized by elevated body temperature, autonomic dysfunction, and altered mental status. Prompt recognition and appropriate management are crucial for patient survival.

Key Point: All three syndromes represent medical emergencies requiring immediate intervention and intensive care support.

Malignant Hyperthermia (MH)

Definition

Malignant hyperthermia is a life-threatening disorder of skeletal muscle homeostasis. Its inheritance is autosomal dominant with an incidence of around 1 in 30,000.

Common Triggers

  • Suxamethonium (most common)
  • Volatile anesthetics:
    • Halothane
    • Isoflurane
    • Desflurane
    • Sevoflurane

Recognition

Diagnosis can be difficult and it may present insidiously over hours, or as an acute life-threatening event at induction. Hyperthermia itself may be a late feature.

Direct Muscle Effects

  • Masseter muscle spasm (MMS):
    • May indicate MH but is not pathognomonic
    • Occurs in normal patients, especially children, after suxamethonium
    • Causes trismus when relaxation expected
    • Treat prolonged MMS as potential MH

Effects of Increased Metabolism

  • Unexplained increase in ETCO₂
  • Unexplained tachycardia
  • Unexplained tachypnea
  • Unexplained increase in oxygen requirement
  • Temperature changes (late sign)

Management

Immediate Management

  1. Stop all trigger agents
  2. Call for help and allocate specific tasks
  3. Install clean breathing system and hyperventilate with 100% O₂ high flow
  4. Maintain anesthesia with intravenous agent
  5. Abandon/finish surgery as soon as possible
  6. Muscle relaxation with non-depolarizing neuromuscular blocking drug

Monitoring and Treatment

Dantrolene Administration
  • 2.5mg/kg immediate IV bolus
  • Repeat 1mg/kg boluses as required to max 10mg/kg

Supportive Measures

  • Initiate active cooling avoiding vasoconstriction
  • Check plasma creatine kinase (CK) as soon as possible
  • Continuous monitoring of vital signs

Complication Management

  • Hyperkalemia: Calcium chloride, glucose/insulin, sodium bicarbonate
  • Arrhythmias: Magnesium/amiodarone/metoprolol (avoid calcium channel blockers)
  • Metabolic acidosis: Hyperventilate, sodium bicarbonate
  • Myoglobinemia: Forced alkaline diuresis, renal replacement therapy
  • DIC: FFP, cryoprecipitate, platelets

Follow-up

  • Continue monitoring in ICU, repeat dantrolene as necessary
  • Monitor for acute kidney injury and compartment syndrome
  • Repeat CK
  • Consider alternative diagnoses (sepsis, pheochromocytoma, thyroid storm, myopathy)
  • Counsel patient and family members
  • Refer to MH unit

Neuroleptic Malignant Syndrome (NMS)

Definition

A potentially life-threatening complication of treatment with antipsychotic drugs, or abrupt withdrawal of dopamine agonists.

Clinical Tetrad

  • Altered mental status
  • Muscle rigidity
  • Autonomic instability
  • Hyperthermia

Diagnosis and Management

Diagnosis of exclusion: A careful assessment, including physical examination and comprehensive tests, is required to exclude other potential causes.

Emergency Management

  • Immediate cessation of the offending medication
  • Supportive measures: Hydration and cooling
  • Additional treatment if supportive interventions fail:
    • Benzodiazepines
    • Dantrolene
    • Dopaminergic agents (bromocriptine, amantadine)

Follow-up: A delay of at least 2 weeks in restarting antipsychotic treatment is advised following full resolution of an NMS episode.

Serotonin Syndrome (SS)

Definition

Clinical manifestation of excess serotonin in the central nervous system, resulting from the therapeutic use or overdose of serotonergic drugs.

Clinical Triad

  • Neuromuscular excitation
  • Autonomic effects
  • Altered mental status

Diagnosis and Management

Diagnosis: Clinical diagnosis based on Hunter Serotonin Toxicity Criteria (HSTC), of which clonus is a key diagnostic feature.

Severe serotonin toxicity is a medical emergency that often requires emergency treatment.

Treatment Approach
  1. Cessation of the causative drug(s)
  2. Supportive care
  3. Specific anti-serotonergic drugs in select patients (e.g., chlorpromazine, cyproheptadine)

Comparative Analysis: NMS vs Serotonin Syndrome

Feature Neuroleptic Malignant Syndrome Serotonin Syndrome
Causative agents Dopamine antagonists Serotonergic agents
Onset Gradual (days) Rapid (hours)
Similar Features
Cardiovascular Hypertension, tachycardia Hypertension, tachycardia
Respiratory Tachypnea Tachypnea
Thermoregulation Hyperthermia (> 40°C) Hyperthermia (> 40°C)
Autonomic Hypersalivation, diaphoresis Hypersalivation, diaphoresis
Mental status Encephalopathy, stupor, coma Agitation, hypervigilance, delirium
Distinct Features
Reflexes Hyporeflexia Hyperreflexia
Muscle tone 'Lead-pipe' rigidity Rigidity with clonus
Pupils Normal pupils Dilated pupils
Bowel sounds Reduced, sluggish Hyperactive
Laboratory Findings
Increased CK, leucocytosis, low serum iron, acidosis More commonly no specific lab findings
Management
Dantrolene, amantadine, bromocriptine Benzodiazepines, cyproheptadine

Key Differentiating Features

Malignant Hyperthermia

  • Setting: Perioperative, anesthesia-related
  • Key sign: Masseter muscle spasm
  • Treatment: Dantrolene is specific treatment
  • Onset: Acute during anesthesia

Neuroleptic Malignant Syndrome

  • Setting: Antipsychotic use or dopamine withdrawal
  • Key sign: "Lead-pipe" rigidity, bradykinesia
  • Treatment: Dopamine agonists, dantrolene
  • Onset: Gradual (days to weeks)

Serotonin Syndrome

  • Setting: Serotonergic medication use
  • Key sign: Hyperreflexia, clonus, agitation
  • Treatment: Cyproheptadine, benzodiazepines
  • Onset: Rapid (hours)